This trial is testing a new chemotherapy drug to treat AML. They are trying to find the best dose of the drug to minimize side effects while still being effective.
1 Primary · 8 Secondary · Reporting Duration: From the first date of intervention until the first documented progression or the date of death from any causes, whichever came first, assessed up to 100 months
24 Total Participants · 4 Treatment Groups
Primary Treatment: Calaspargase pegol-mknl · No Placebo Group · Phase 1
Age 18 - 65 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: